Gaps in our knowledge and future research on the endocannabinoid system and the painful phenomenon

Angela Maria Sousa; Alexandre Slullitel; Thiago Siqueira Serra

doi:10.5935/2595-0118.20230025-en

Artigo de Revisão

Gaps in our knowledge and future research on the endocannabinoid system and the painful phenomenon

As lacunas do nosso conhecimento e as pesquisas futuras sobre o sistema endocanabinoide e o fenômeno doloroso

Angela Maria Sousa; Alexandre Slullitel; Thiago Siqueira Serra

http://dx.doi.org/10.5935/2595-0118.20230025-en BrJP, vol.6, nSuppl. 2, p.97-102, 2023

PDF

SciELO

Downloads: 0

Abstract

BACKGROUND AND OBJECTIVES: This article aimed to discuss and point out the main gaps and bottlenecks in national and international clinical research regarding medicinal cannabinoid compounds and their respective relevance to pain management practices. Other objectives were to establish standards and regulations for testing the quality, efficacy, and safety of cultivation and manufacturing of cannabis products (similar to biopharmaceutical standards) before prescribing or marketing, and to investigate approaches in order to establish robust guidelines for cannabinoid-influenced driving.
CONTENTS: A search with the terms “cannabinoids” and “pain” in the domain www.clinicaltrials.gov, international data platform for registration of clinical research trials, found only two Brazilian studies, on fibromyalgia and chronic headache. The search for the term “cannabinoid” in Plataforma Brasil returned only nine mentions of studies related to pain, most of them being case reports or observational studies, without active intervention or control group.
CONCLUSION: There are still few clinical, randomized, controlled trials evaluating effective doses, routes and interval of administration, pharmacological interaction with opioids or among the various cannabinoids, interaction with adjunct analgesics, potential injury in the context of long-term use, and individual factors that predispose to indiscriminate cannabinoid use.

Keywords

Cannabis, Pain, Research on Health Services

Resumo

JUSTIFICATIVA E OBJETIVOS: O presente artigo teve como objetivo debater e apontar as principais lacunas e gargalos na pesquisa clínica nacional e internacional relativas aos compostos canabinoides de uso medicinal e suas respectivas relevâncias nas práticas relacionadas ao controle da dor. Outros objetivos foram estabelecer padrões e regulamentos para testar a qualidade, eficácia e segurança de cultivo e fabricação de produtos de cannabis (semelhantes aos padrões biofarmacêuticos) antes de prescrever ou comercializar, e investigar abordagens a fim de estabelecer orientações robustas para dirigir sob influência de canabinoides.
CONTEÚDO: Uma pesquisa com os termos “canabinoides” e “pain” no domínio do www.clinicaltrials.gov, plataforma internacional de dados de registro de ensaios de pesquisa clínica, cita apenas dois estudos brasileiros, sobre fibromialgia e cefaleia crônica. A busca do termo “canabinoide” na Plataforma Brasil retornou apenas nove menções de estudos relacionados ao tema dor, sendo a maioria relatos de casos ou estudos observacionais, sem intervenção ativa, ou sem grupo controle.
CONCLUSÃO: Ainda há poucos estudos clínicos, randomizados e controlados avaliando doses eficazes, vias e intervalo de administração, interação farmacológica com opioides ou entre os diversos canabinoides, interação com analgésicos adjuvantes, lesões potenciais no contexto do uso a longo prazo e fatores individuais que predisponham ao uso indiscriminado dos canabinoides.

Palavras-chave

Cannabis, Dor, Pesquisa sobre Serviços de Saúde

Referências

1 Sites BD. Cannabinoids and pain medicine: what could possibly go wrong? Reg Anesth Pain Med. 2020;45(7):485.

2 Medicamentos à base de cannabis passarão a ser vendidos a partir de agosto em farmácias brasileiras. Disponível em: https://www.oliberal.com/brasil/medicamentos-a-base-de-cannabis-passarao-a-ser-vendidos-a-partir-de-agosto-em-farmacias-brasileiras-1.554165.

3 Liu J, Chen H, Newmaster S, Wang S, Liu C. Global trends in cannabis and cannabidiol research from the year 1940 to 2019. Curr Pharm Biotechnol. 2021;22(5):579-91.

4 USP tem a maior produção científica mundial sobre canabidiol. [citado 21 de fevereiro de 2022]; Disponível em: https://jornal.fmrp.usp.br/usp-tem-a-maior-producao-cientifica-mundial-sobre-canabidiol/

5 Pacher P, Kogan NM, Mechoulam R. Beyond THC and endocannabinoids. Annu Rev Pharmacol Toxicol. 2020;60(1):637-59.

6 Gachet MS, Rhyn P, Bosch OG, Quednow BB, Gertsch J. A quantitative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;976-77:6-18.

7 Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001;98(7):3662-5.

8%20601 [Internet]. [citado 19 de julho de 2022]. Disponível em: https://www.congress.gov/bill/116th-congress/housebill/%20601?q={%E2%80%9Csearch%E2%80%9D:[%E2%80%9Cmedical+cannabis+research+%20act%E2%80%9D]}

9 Survey-reveals-skyrocketing-interest-in-marijuana-and-cannabinoids-for-pain [Internet]. [citado 19 de julho de 2022]. Disponível em: https://www.asahq.org/about-asa/newsroom/news-releases/2019/08/survey-reveals-skyrocketing-interest-in-marijuana-and-cannabinoids-for-pain

10 Groce E. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. J Med Regul. 2018;104(4):32.

11 Bonomo Y, Souza JDS, Jackson A, Crippa JAS, Solowij N. Clinical issues in cannabis use. Br J Clin Pharmacol. 2018;84(11):2495-8.

12 Badolia I. Cannabinoids Future Research. Em: Narouze SN, organizador. Cannabinoids and Pain [Internet]. Cham: Springer International Publishing; 2021 [citado 7 de julho de 2022]. 325-32p. Disponível em: https://link.springer.com/10.1007/978-3-030-69186-8_40

13 Habib G, Avisar I. The consumption of cannabis by fibromyalgia patients in Israel. Pain Res Treat. 2018;2018:1-5.

14 Banerjee R, Erridge S, Salazar O, Mangal N, Couch D, Pacchetti B, Sodergren MH. Real world evidence in medical cannabis research. Ther Innov Regul Sci. 2022;56(1):8-14.

15 Haroutounian S, Arendt-Nielsen L, Belton J, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Finn DP, Finnerup NB, Fisher E, Fogarty AE, Gilron I, Hohmann AG, Kalso E, Krane E, Mohiuddin M, Moore RA, Rowbotham M, Soliman N, Wallace M, Zinboonyahgoon N, Rice ASC. Intenational Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl 1):S117-S124.

16 Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, Segelcke D, Sena C, Thomas J, Vollert J, Wever K, Alaverdyan H, Barakat A, Barthlow T, Bozer ALH, Davidson A, Diaz-delCastillo M, Dolgorukova A, Ferdousi MI, Healy C, Hong S, Hopkins M, James A, Leake HB, Malewicz NM, Mansfield M, Mardon AK, Mattimoe D, McLoone DP, Noes-Holt G, Pogatzki-Zahn EM, Power E, Pradier B, Romanos-Sirakis E, Segelcke A, Vinagre R, Yanes JA, Zhang J, Zhang XY, Finn DP, Rice ASC. Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain. 2021;162(Suppl 1):S26-S44.

17 Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, Eccleston C. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66.

18 Mohiuddin M, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Haroutounian S, Moore A, Rice ASC, Wallace M, Park R, Gilron I. General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. Pain. 2021;162(Suppl 1):S80-S96.

19 Moore RA, Fisher E, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, Eccleston C. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2021;162(Suppl 1):S67-S79.

20 Haroutounian S, Gilron I, Belton J, Degenhardt L, Di Forti M, Finn DP, Fogarty A, Kalso E, Krane E, Moore RA, Rowbotham M, Wallace M, Rice ASC. Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl 1):S110-S116.

Submetido em:
19/07/2022

Aceito em:
21/03/2023

Gaps in our knowledge and future research on the endocannabinoid system and the painful phenomenon

As lacunas do nosso conhecimento e as pesquisas futuras sobre o sistema endocanabinoide e o fenômeno doloroso

Angela Maria Sousa; Alexandre Slullitel; Thiago Siqueira Serra

Abstract

Keywords

Resumo

Palavras-chave

Referências

Links

Compartilhar

BrJP